You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
和黃醫藥(00013.HK):愛優特® 及蘇泰達®按現行條款成功續約中國國家醫保藥品目錄
格隆匯 12-13 12:35

格隆匯12月13日丨和黃醫藥(00013.HK)宣佈,根據2023年的簡易續約規則愛優特®(ELUNATE®,呋喹替尼/fruquintinib)及蘇泰達®(SULANDA®,索凡替尼/surufatinib)獲中國國家醫療保障局("國家醫保局")成功續約,將繼續納入自2024年1月1日起生效的新版《國家基本醫療保險、工傷保險和生育保險藥品目錄》("醫保藥品目錄"),與並維持與現行兩年期協議相同的條款。

和黃醫藥高級副總裁兼首席商務官(中國)陳洪先生表示:"在醫保的幫助下,我們的創新藥物得以快速覆蓋到全國更多有需要的患者。近年來,國家醫保局採取了包括談判准入、非獨家藥品競價准入及對於已經進入目錄的產品的簡易續約規則等在內的一系列醫保新政策。這些新政策進一步穩固了創新藥行業健康發展的根基,保障並持續提高患者對創新藥的可及性,讓百姓真正受惠醫藥創新。"愛優特®於2020年1月1日首次獲納入醫保藥品目錄,用治療轉移性結直腸癌。2020年,結直腸癌是中國發病率第三高的癌症,每年約新增555,000例新症。

蘇泰達®於2022年1月1日首次獲納入醫保藥品目錄,用治療非胰腺及胰腺神經內分泌瘤。在中國,據估計2020年約新增71,300例神經內分泌瘤新症,患者總數或高達三十萬人。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account